翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

交易中 11-02 13:44:22

32.400

+0.040

+0.12%

最高32.700	最低31.600	成交量690.62万
今开32.380	昨收32.360	日振幅3.40%
总市值1,965亿	流通市值1,965亿	总股本60.64亿
成交额2.21亿	换手率0.11%	流通股本60.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":32.4,"timestamp":1793598261684,"preClose":32.36,"halted":0,"volume":6906197,"delay":0,"changeRate":0.0012360939431396523,"floatShares":6064000000,"shares":6064000000,"eps":1.0982285929482656,"marketStatus":"交易中","change":0.04,"latestTime":"11-02 13:44:22","open":32.38,"high":32.7,"low":31.6,"amount":221326755,"amplitude":0.033993,"askPrice":32.4,"askSize":26000,"bidPrice":32.36,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":1.3080528414222727,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793607000000},"marketStatusCode":2,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":32.36,"dividendRate":0.014981,"openAndCloseTimeList":[[1793583000000,1793592000000],[1793595600000,1793606400000]],"volumeRatio":1.101175,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","159938","06990","LU0039217434.USD","LU0455707207.USD","LU0348825331.USD","02162","06996","LU0979878070.USD","IE00B031HY20.USD","BK0028","02268","01530","03692","01177","HK0000320264.USD","LU1969619763.USD","01952","09939","01276","01548","02269","LU1226287529.USD","02596","06821","01093","09926","LU0823426480.USD","01951","00013","09996","03759","LU2488822045.USD","LU0828237510.HKD","06030","LU1064131003.USD","KCE","06078","LU0607220059.USD","KURE","LU0708995153.HKD","01801","LU1794554557.SGD","09966","02096","02273","600030","LU0708995583.HKD","LU0348766576.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157232716","title":"异动解读｜翰森制药盘中上涨3.3%，创新药板块走强叠加ADC出海逻辑获关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1157232716","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157232716?lang=zh_cn&edition=full","pubTime":"2026-10-29 13:18","pubTimestamp":1793251110,"startTime":"0","endTime":"0","summary":"10月29日，翰森制药盘中上涨3.3%，报33.2港元，成交额1.96亿港元。此次异动主要与创新药板块延续强势有关，市场继续聚焦中国创新药出海主线，ADC、双抗等方向再获资金关注。公司此前与罗氏达成ADC战略合作及许可协议，涵盖两个临床前ADC项目及多个平台项目，翰森将获得4亿美元首付款、1.1亿美元一周年付款，并有资格获得逾150亿美元里程碑付款及销售分成。机构普遍认为，这进一步验证其ADC平台全球竞争力，并提升海外价值兑现能见度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰森制药盘中上涨，ADC出海合作引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172651881","title":"异动解读｜翰森制药盘中上涨3.02%，创新药板块走强叠加ADC出海逻辑获关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1172651881","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172651881?lang=zh_cn&edition=full","pubTime":"2026-10-28 11:24","pubTimestamp":1793157891,"startTime":"0","endTime":"0","summary":"10月28日，翰森制药盘中上涨3.02%，报32.8港元，成交额2.12亿港元。此次异动与创新药板块整体走强直接相关，市场继续关注中国创新药出海主线，ADC、双抗等赛道再获资金追捧。公司此前与罗氏达成ADC战略合作及许可协议，涵盖两个临床前ADC项目及多个平台项目，翰森将获得4亿美元首付款、1.1亿美元一周年付款，并有资格获得逾150亿美元里程碑付款及销售分成；多家机构认为，这进一步验证其ADC平台全球竞争力并提升海外价值兑现能见度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰森制药盘中走强，ADC出海逻辑再获关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678243653","title":"创新药概念板块走强 恒瑞医药（01276）涨超11% 券商看好ADC、双抗等出海赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2678243653","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678243653?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:32","pubTimestamp":1793154754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念板块走强，截至发稿，恒瑞医药 涨11.14%，金斯瑞生物涨9.39%，康方生物涨4.70%，诺诚健华涨3.50%，欧康维视生物-B涨3.33%，亚盛医药涨2.65%，翰森制药涨2.32%。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994616","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","BK1576","LU0348783233.USD","IE00B543WZ88.USD","BK1583","BK0196","LU1997245177.USD","06978","LU1064130708.USD","LU2778985437.USD","01477","BK0188","LU0359201885.HKD","LU0634319403.HKD","LU0417516738.SGD","09926","LU1328615791.USD","KURE","LU1781817850.SGD","LU2328871848.SGD","LU0417516571.SGD","MEDX","IBBQ","KCE","LU0417516902.SGD","BK1589","BK1191","06855","LU2289578879.USD","HK0000320264.USD","BK1161","LU1961090484.USD","159992","LU0405327148.USD","IE00B5MMRT66.SGD","LU1820825898.SGD","LU2097828474.EUR","LU0348827113.USD","BK0183","LNGR","01548","03692","01276","LU1720050803.USD","LU0348767384.USD","LU2476274720.SGD","LU0348735423.USD","LU1655091616.SGD","600276","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678140953","title":"医药股走低 恒生生物科技指数跌2.48% 映恩生物-B（09606）大跌31.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678140953","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678140953?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:18","pubTimestamp":1793081937,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股走低，恒生生物科技指数大幅跌2.48%。成分股中，映恩生物-B跌31.05%，亚盛医药跌6.70%，科伦博泰生物跌5.96%，三生制药跌5.10%，石药集团跌4.25%，康方生物跌3.63%，中国生物制药跌3.26%，翰森制药跌3.10%，百济神州跌3.03%。近两个月连锁药房密集推出股权激励，驱动板块逻辑从“政策博弈”转向“业绩锚定”。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994559","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1515","09606","BK1593","IE0008368742.USD","LU0348784397.USD","BK1583","IE00B5MMRT66.SGD","01093","LU0348766576.USD","HK0000500386.USD","IE00BZ08YR35.GBP","06855","LU0634319403.HKD","LU0140636845.USD","HK0000252152.HKD","LU0348783233.USD","LU0588546209.SGD","LU1328277881.USD","09939","LU1961090484.USD","LU2488822045.USD","LU1969619763.USD","LU0315179316.USD","06160","06990","159938","KURE","LU1226287529.USD","LU1226287875.USD","SG9999004220.SGD","LU1226287792.SGD","09926","01530","LU1993786604.SGD","LU1226288253.USD","03692","LU0348827113.USD","LU0880133367.SGD","LU0561508036.HKD","01177","LU1719994722.HKD","LU0417516902.SGD","LU2476274720.SGD","IE00B543WZ88.USD","IE0008369823.USD","LU0417516738.SGD","LU2039709279.SGD","LU0501845795.SGD","LU0314109678.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171087633","title":"异动解读｜翰森制药盘中下跌3.1%，罗氏ADC合作交易热度边际降温","url":"https://stock-news.laohu8.com/highlight/detail?id=1171087633","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171087633?lang=zh_cn&edition=full","pubTime":"2026-10-27 11:24","pubTimestamp":1793071490,"startTime":"0","endTime":"0","summary":"10月27日，翰森制药盘中下跌3.1%，报31.88港元，成交额1.65亿港元。近期可对应的公开消息仍集中于公司与罗氏达成ADC战略合作及许可协议。该协议覆盖两个临床前ADC项目及多个基于翰森技术平台开发的项目，翰森将获得4亿美元首付款、1.1亿美元一周年付款，并有资格获得逾150亿美元里程碑付款及销售分成。当前股价回落，或显示前期利好催化后的短线交易热度有所消化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰森制药走弱，ADC合作热度降温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678415671","title":"瑞银：翰森制药(03692)Mo-Rez铂耐药卵巢癌数据正面 维持“买入”评级 目标价50.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678415671","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678415671?lang=zh_cn&edition=full","pubTime":"2026-10-27 11:18","pubTimestamp":1793071122,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，维持翰森制药“买入”评级及50.8港元目标价。该行指出，欧洲肿瘤内科学会年会2026公布的Mo-Rez治疗铂耐药卵巢癌更新数据，以及HS-20122一期临床数据均表现正面。瑞银认为，疗效的持久性是此次数据的重要正面因素。该行认为，相关数据进一步支持选定剂量，并支持GSK加快Mo-Rez的全球三期临床开发。目前，卵巢癌及子宫内膜癌领域已有五项关键三期研究正在进行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677491493","title":"翰森制药午前涨近4% 高盛指此举有助公司全球价值变现能见度提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2677491493","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677491493?lang=zh_cn&edition=full","pubTime":"2026-10-23 11:58","pubTimestamp":1792727880,"startTime":"0","endTime":"0","summary":"模拟交易客户端翰森制药午前涨近4%，截至发稿，股价上涨3.58%，现报33港元，成交额4.10亿港元。高盛发布研报称，翰森制药宣布与罗氏订立战略合作及许可协议，涵盖两个临床前ADC项目，以及多个以罗氏提出靶点、并运用翰森专有ADC技术平台的额外项目，属该公司首个平台型合作，进一步验证其ADC能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-23/doc-iniweqhu4973537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4504","LU0096364046.USD","LU1868836914.USD","LU2471134952.CNY","LU2896262040.SGD","IE00BSNM7G36.USD","BK4585","LU2265009873.SGD","BK4588","LU1868836591.USD","LU2237443622.USD","IE00BFXG1179.USD","LU0251131958.USD","LU0345770308.USD","LU0210536198.USD","IE00B19Z3581.USD","LU1868836757.USD","LU2471134879.HKD","BK1589","BK4533","LU1868837300.USD","IE0034235188.USD","BK4552","GSX","LU0742534661.SGD","LU2237443382.USD","BK1191","IE0004091025.USD","BK4550","LU0061475181.USD","LU1791807156.HKD","IE0004086264.USD","BK1583","LU0942090050.USD","BK4516","LU2237443895.HKD","LU1894683348.USD","LU2471134523.USD","03692","LU0251142724.SGD","LU1894683264.USD","LU0106831901.USD","LU2750360997.AUD","LU1868837136.USD","LU1668664300.SGD","IE00B19Z3B42.SGD","BK4127","LU2237438978.USD","LU2237443549.SGD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677919751","title":"港股异动 | 翰森制药(03692.HK)涨近3% 与扩大与罗氏ADC合作 高盛指此举有助公司全球价值变现能见度提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2677919751","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677919751?lang=zh_cn&edition=full","pubTime":"2026-10-23 10:40","pubTimestamp":1792723240,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03692","BK1191","BK1583","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188526810","title":"异动解读｜翰森制药盘中上涨3.01%，机构看好罗氏ADC合作价值兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=1188526810","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188526810?lang=zh_cn&edition=full","pubTime":"2026-10-23 10:37","pubTimestamp":1792723036,"startTime":"0","endTime":"0","summary":"10月23日，翰森制药盘中上涨3.01%，报32.82港元，成交额3.04亿港元。消息面上，机构最新维持公司跑赢行业评级并给出52港元目标价，核心依据是公司与罗氏新近落地的ADC多项目合作进一步验证平台全球竞争力。此次合作潜在总金额超155亿美元，包含4亿美元首付款、1.1亿美元一周年付款，以及逾150亿美元里程碑付款和销售分成；合作模式也由单一分子授权升级为多项目授权叠加平台合作。机构认为，首付款有望增厚利润与现金流，后续里程碑及分成提升海外价值兑现能见度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰森制药盘中上涨，罗氏ADC合作价值获看好","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677916941","title":"中金：维持翰森制药(03692)“跑赢行业”评级 目标价52港元 ADC平台价值持续兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2677916941","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677916941?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:47","pubTimestamp":1792720077,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持翰森制药“跑赢行业”评级，目标价52.00港元，对应2026年及2027年市盈率分别为43.9倍及42.3倍，潜在上行空间为51.25%。该行认为，此次大额BD进一步验证了翰森ADC平台的全球竞争力。中金认为，此次大额BD进一步验证了翰森ADC平台的全球竞争力，首付款有望增厚公司利润及现金流，长期里程碑与销售分成则提供持续的海外价值兑现空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677376909","title":"翰森155亿美元、和黄12.95亿美元交易同周落地，中国ADC资产被跨国药企天价扫货","url":"https://stock-news.laohu8.com/highlight/detail?id=2677376909","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677376909?lang=zh_cn&edition=full","pubTime":"2026-10-22 15:57","pubTimestamp":1792655852,"startTime":"0","endTime":"0","summary":"翰森这笔交易规模在国产创新药对外授权中居第二位，仅次于石药集团与阿斯利康最高约185亿美元的合作，超过恒瑞医药与百时美施贵宝潜在总金额约152亿美元的BD合作。其次，ADC赛道已被商业验证。2026年以来，石药—阿斯利康、翰森—罗氏、恒瑞—百时美施贵宝、信达—辉瑞等头部交易，无一例外涉及多项目组合或平台能力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792653762093863976","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["03692","BK1191","BK1589","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677932835","title":"携手罗氏超155亿美元合作落地：翰森制药国际化再升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2677932835","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677932835?lang=zh_cn&edition=full","pubTime":"2026-10-22 15:15","pubTimestamp":1792653300,"startTime":"0","endTime":"0","summary":"2026年10月17日，翰森制药（03692）与罗氏签署第二份ADC（抗体偶联药物）战略合作及许可协议。这笔交易潜在总额超过155亿美元，包含首付款4亿美元，另有1.1亿美元一周年付款，开发、注册及商业化里程碑潜在超过150亿美元。值得注意的是，本次交易标的并非单个分子；时隔一年再度签约，双方合作模式已经从单一分子授权，升级为多项目授权叠加平台合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610223904062569.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610223904062569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","03692","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677396929","title":"招银国际：升翰森制药(03692.HK)目标价至50.54港元 罗氏合作及ESMO数据强化ADC价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2677396929","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677396929?lang=zh_cn&edition=full","pubTime":"2026-10-22 14:14","pubTimestamp":1792649667,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","03692","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168585767","title":"异动解读｜翰森制药盘中下跌3.08%，罗氏ADC合作利好后股价回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1168585767","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168585767?lang=zh_cn&edition=full","pubTime":"2026-10-22 10:21","pubTimestamp":1792635693,"startTime":"0","endTime":"0","summary":"10月22日，翰森制药盘中下跌3.08%，报33.32港元，成交额9355.0万港元。近期可见消息面仍集中在公司与罗氏签署多项目ADC战略合作及许可协议。根据已披露条款，翰森将获得4亿美元首付款，并于协议一周年再获1.1亿美元付款，另有资格获得逾150亿美元里程碑付款及销售分成。最新机构观点维持买入或增持，并将目标价上调至约50港元，认为合作由单一资产拓展至平台级合作，进一步验证其ADC技术平台与早期发现能力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"翰森制药盘中走低，罗氏ADC合作后回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677442640","title":"小摩：翰森制药(03692)与罗氏合作印证公司能力 目标价50港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677442640","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677442640?lang=zh_cn&edition=full","pubTime":"2026-10-21 14:18","pubTimestamp":1792563536,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，翰森制药(03692)宣布与罗氏(Roche)签订多项目抗体药物偶联物(ADC)合作协议，涵盖两款翰森临床前ADC，以及多个针对罗氏提出靶点的ADC项目;该行维持对翰森制药“增持”评级，目标价50港元，料股价有正面反应，有单位数百分比上升空间。根据协议，翰森将获得4亿美元首付款，以及于协议一周年获得1.1亿美元付款。翰森亦有资格获得超过150亿美元的开发、获批及销售里程碑付款，另加特许权使用费。该行认为，新合作协议将双方合作关系由单一ADC资产，转为部分建立在翰森技术平台之上的产品组合，并将此视为对翰森平台及早期药物发现能力的另一重要证明。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677640640","title":"【券商聚焦】华泰证券维持翰森制药（03692）买入评级 指ADC平台获MNC认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2677640640","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677640640?lang=zh_cn&edition=full","pubTime":"2026-10-21 14:08","pubTimestamp":1792562924,"startTime":"0","endTime":"0","summary":"翰森制药将有资格获得4亿美元首付款、潜在超过150亿美元的里程碑付款以及销售分成。本次合作包括两个翰森制药临床前ADC项目，及多个由罗氏提议靶点、依托翰森自有ADC创新技术平台开发的ADC项目。ADC平台质量已获多项MNC合作背书。维持“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994103","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677642431","title":"【券商聚焦】中泰国际：创新药与医疗AI技术出海捷报频传","url":"https://stock-news.laohu8.com/highlight/detail?id=2677642431","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677642431?lang=zh_cn&edition=full","pubTime":"2026-10-21 13:28","pubTimestamp":1792560508,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，中国创新药企业继2026年上半年出海金额同比增加36%至1,200亿美元后，下半年仍然捷报频出。港股上市的企业中，9月恒瑞医药9月与诺和诺德达成总额最高26亿美元的授权协议后，创新药龙头翰森制药与AI技术平台开发商剂泰科技近日分别与礼来及罗氏达成战略合作。该机构重申聚焦创新药龙头观点，并看好中国AI制药新技术。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994121","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","BK1521","LU1188198961.HKD","KCE","03692","LU0228659784.USD","IE00B031HY20.USD","LU2242644610.SGD","01276","LU0502904849.HKD","LU1831875114.USD","01177","LU1303224171.USD","IBBQ","IE00BZ08YS42.EUR","LU1951186391.HKD","KURE","LU1008478684.HKD","LU1023057109.AUD","LU0244354667.USD","06978","150261","LU0359202008.SGD","IE00BZ08YT58.USD","LU2097828557.USD","LU1807302812.USD","SG9999004220.SGD","LU0463099449.HKD","IE00B5MMRT66.SGD","06160","159992","MEDX","00013","LU0067412154.USD","LU1226287792.SGD","LU1226287875.USD","01801","LU1813983027.USD","LU1719994722.HKD","07666","BK1161","LU0828237510.HKD","LU0140636845.USD","LU2488822045.USD","LU0607220059.USD","LU0149534421.HKD","LU0072913022.USD","LNGR","01093","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676666032","title":"ADC出海新纪录，翰森制药冲高9%，港股通创新药大受提振！CXO、互联网医疗齐升，港股通医疗ETF华宝爆量上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2676666032","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676666032?lang=zh_cn&edition=full","pubTime":"2026-10-20 19:08","pubTimestamp":1792494480,"startTime":"0","endTime":"0","summary":"A股医疗板块低开高走，迪安诊断20CM涨停，医疗ETF华宝收复半年线；创新药延续修复，药ETF华宝四连涨。港股大市调整，医药板块走出独立行情，创新药、CXO、互联网医疗等多点开花！港股通医疗ETF华宝、港股通创新药ETF华宝标的指数盘中分别上探3%、2.4%，收涨1.58%、1.49%。超155亿美元BD大单提振，翰森制药盘中暴拉逾9%，收涨8.32%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-10-20/doc-inivwpzm6468595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","IBBQ","159992","CXO","03692","06978","MEDX","BK1583","BK1589","WX","LNGR","BK1574","512170","FLHK","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676654308","title":"高盛：翰森制药(03692.HK)扩大与罗氏ADC合作 全球价值变现能见度提升 目标价52.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676654308","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676654308?lang=zh_cn&edition=full","pubTime":"2026-10-20 13:45","pubTimestamp":1792475125,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1589","03692","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.0833},{"period":"3month","weight":0.0137},{"period":"6month","weight":-0.1151},{"period":"1year","weight":-0.0401},{"period":"ytd","weight":-0.0901}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0536},{"period":"3month","weight":-0.1001},{"period":"6month","weight":-0.0963},{"period":"1year","weight":-0.1137},{"period":"ytd","weight":-0.0911}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002579},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.012814},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023358},{"month":4,"riseRate":0.571429,"avgChangeRate":0.033967},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.005202},{"month":6,"riseRate":0.571429,"avgChangeRate":0.039399},{"month":7,"riseRate":0.625,"avgChangeRate":0.011392},{"month":8,"riseRate":0.75,"avgChangeRate":0.028858},{"month":9,"riseRate":0.625,"avgChangeRate":-0.028026},{"month":10,"riseRate":0.125,"avgChangeRate":-0.009001},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063438},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016882}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}